AU2022407450A1 — CNP Therapy
Assigned to Biomarin Pharmaceutical Inc · Expires 2024-07-11 · 2y expired
What this patent protects
The present disclosure relates, in general, to measures of efficacy in patients receiving C-type natriuretic peptide (CNP) therapy to treat a skeletal dysplasia, short stature or bone-related disorders.
USPTO Abstract
The present disclosure relates, in general, to measures of efficacy in patients receiving C-type natriuretic peptide (CNP) therapy to treat a skeletal dysplasia, short stature or bone-related disorders.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.